The Araxa Biosciences GmbH was jointly founded by EMBL, EMBLEM and Xlife Sciences AG, a Swiss
company with a focus on investing in promising technologies in the life science industry. Araxa applies its proprietary protein engineering technology platform, which was developed at the EMBL, to offer protein engineering for medical (e.g. antibody-drug conjugates, research and biomaterial applications.